Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19 vaccination.

"appendix a supplementary data the following are the supplementary data to this article: supplementary data 1 data availability some of the data is confidential."

"Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Mary A Staat reports a relationship with Pfizer that includes: funding grants. Mary A Staat reports a relationship with Merck & Co Inc that includes: funding grants. Mary A Staat reports a relationship with UpToDate that includes: consulting or advisory. Donna S. Hummell reports a relationship with Merck & Co Inc that includes: consulting or advisory. Kathryn M. Edwards reports a relationship with Bionet that includes: consulting or advisory. Kathryn M. Edwards reports a relationship with IBM that includes: consulting or advisory. Kathryn M. Edwards reports a relationship with Member Data that includes: consulting or advisory. Kathryn M. Edwards reports a relationship with Sanofi, X-4 Pharma, Seqirus, Moderna, Pfizer, Merck, Roache, Novavax, Brighton Collaboration that includes: consulting or advisory. UpToDate fees for Mary A. Stadt were classified as royalties that are unrelated to this work. Consultative work by Kathryn M. Edwards for X-4 Pharma, Seqirus, Moderna, Pfizer, Merck, Roche, Novavax, Brighton Collaboration was serving on Safety and Monitoring Boards. Consultative work by Donna S. Hummel for Merck was for eDMC monitoring for clinical trial."

"Financial support This work was supported by the Centers for Disease Control and Prevention Clinical Immunization Safety Assessment (CISA) Project contracts 200-2012-53661 to Cincinnati Children’s Hospital Medical Center, 200-2012-50430 to Vanderbilt University Medical Center and 200-2012-53664 to Johns Hopkins University."